Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.8K citations · Full text

Medicine, Genetics, Oncology +14

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16